Regeneron Pharmaceuticals (REGN) Stock Forecast & Price Target

$1,014.59

-25.68 (-2.47%)

(As of 04:33 PM ET)

Regeneron Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 22 Analyst Ratings

Sell
1

Hold
4

Buy
17

Based on 22 Wall Street analysts who have issued ratings for Regeneron Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 22 analysts, 1 has given a sell rating, 4 have given a hold rating, 16 have given a buy rating, and 1 has given a strong buy rating for REGN.

Consensus Price Target

$1,118.62
10.25% Upside

According to the 22 analysts' twelve-month price targets for Regeneron Pharmaceuticals, the average price target is $1,118.62. The highest price target for REGN is $1,300.00, while the lowest price target for REGN is $720.00. The average price target represents a forecasted upside of 10.25% from the current price of $1,014.59.

Get the Latest News and Ratings for REGN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Regeneron Pharmaceuticals and its competitors.

REGN Analyst Ratings Over Time

Type	Current Forecast 10/4/23 to 10/3/24	1 Month Ago 9/4/23 to 9/3/24	3 Months Ago 7/6/23 to 7/5/24	1 Year Ago 10/4/22 to 10/4/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	16 Buy rating(s)	16 Buy rating(s)	16 Buy rating(s)	19 Buy rating(s)
Hold	4 Hold rating(s)	3 Hold rating(s)	4 Hold rating(s)	6 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$1,118.62	$1,108.45	$1,027.55	$897.91
Forecasted Upside	10.25% Upside	-5.16% Downside	-0.65% Downside	10.17% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

44-year Wall Street Vet: “Permanent devastation is coming to America” (Ad)

After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. But now a looming disaster is threatening America. And it's unlike anything we've ever experienced before.

The information in this video is crucially valuable.

REGN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

REGN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Regeneron Pharmaceuticals Stock vs. The Competition

Type	Regeneron Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.77	2.78	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	10.25% Upside	848.47% Upside	7.73% Upside
News Sentiment Rating	Positive News See Recent REGN News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/24/2024	Leerink Partnrs 0 of 5 stars	D. Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
9/24/2024	Royal Bank of Canada 4 of 5 stars		Lower Target	Outperform ➝ Outperform	$1,282.00 ➝ $1,252.00	+21.91%
9/24/2024	BMO Capital Markets 4 of 5 stars		Reiterated Rating	Outperform ➝ Outperform	$1,300.00 ➝ $1,300.00	+24.61%
9/24/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$1,200.00 ➝ $1,200.00	+13.87%
9/24/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Market Perform	$1,175.00 ➝ $1,077.00	-1.37%
9/23/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$1,200.00 ➝ $1,200.00	+7.67%
Get the Latest News and Ratings for REGN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
9/16/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral ➝ Neutral	$1,015.00 ➝ $1,015.00	-12.15%
8/23/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$1,166.00 ➝ $1,242.00	+3.39%
8/2/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$1,150.00 ➝ $1,200.00	+10.89%
8/2/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$1,180.00 ➝ $1,300.00	+19.90%
8/2/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$1,200.00 ➝ $1,220.00	+12.61%
7/23/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$1,030.00 ➝ $1,200.00	+12.39%
7/11/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$1,183.00 ➝ $1,182.00	+8.81%
6/27/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$1,152.00 ➝ $1,152.00	+7.78%
6/25/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$1,060.00 ➝ $1,170.00	+9.97%
5/14/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$1,150.00	+17.71%
4/17/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$1,090.00 ➝ $1,099.00	+21.95%
4/12/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Underperform ➝ Underperform	$710.00 ➝ $720.00	-21.77%
3/12/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$1,125.00	+16.65%
11/28/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$935.00 ➝ $937.00	+17.00%
11/9/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold	$800.00	-2.77%
11/3/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$950.00	+16.02%
9/15/2023	Westpark Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold
8/21/2023	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Market Perform	$950.00 ➝ $1,050.00	+29.25%
6/28/2023	22nd Century Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Downgrade
6/28/2023	500.com Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
6/28/2023	VNET Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Downgrade
6/28/2023	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$800.00 ➝ $760.00	+6.13%
5/5/2023	888 Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
5/5/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$976.00 ➝ $895.00	+17.59%
3/28/2023	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy
3/23/2023	EF Hutton Acquisition Co. I Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$853.00 ➝ $862.00	+14.73%
1/30/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$775.00 ➝ $875.00	+17.79%
10/3/2022	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$796.00 ➝ $970.00	+32.49%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 05:29 PM ET.

Should I Buy Regeneron Pharmaceuticals Stock? REGN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, October 1, 2024. Please send any questions or comments about these Regeneron Pharmaceuticals pros and cons to contact@marketbeat.com.

Regeneron Pharmaceuticals
Bull Case

Here are some ways that investors could benefit from investing in Regeneron Pharmaceuticals, Inc.:

Regeneron Pharmaceuticals has a strong buy rating from multiple analysts, indicating positive market sentiment towards the company's future performance.
Recent insider activity shows that company directors and executives are investing in the stock, which can be seen as a vote of confidence in the company's growth prospects.
Regeneron Pharmaceuticals has a solid track record of developing innovative biotech products, which could lead to potential revenue growth and market expansion.
The company's stock price has shown resilience and stability, even during market fluctuations, providing a sense of security to investors.
Analysts have set a consensus target price above the current stock price, suggesting potential for capital appreciation in the near future.

Regeneron Pharmaceuticals
Bear Case

Investors should be bearish about investing in Regeneron Pharmaceuticals, Inc. for these reasons:

Some analysts have downgraded their rating on Regeneron Pharmaceuticals, indicating a level of uncertainty or caution surrounding the company's future performance.
There have been recent insider sales of company stock, which could be interpreted as a lack of confidence in the company's growth potential by those familiar with its operations.
Regeneron Pharmaceuticals operates in a highly competitive industry, facing challenges from other biotech companies that could impact its market position and profitability.
The stock price has experienced fluctuations, potentially indicating volatility that may not align with all investors' risk tolerance levels.
Market conditions and regulatory changes in the biotech sector could pose risks to Regeneron Pharmaceuticals' operations and financial performance.

REGN Forecast - Frequently Asked Questions

: According to the research reports of 22 Wall Street equities research analysts, the average twelve-month stock price forecast for Regeneron Pharmaceuticals is $1,118.62, with a high forecast of $1,300.00 and a low forecast of $720.00.
: 22 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last twelve months. There is currently 1 sell rating, 4 hold ratings, 16 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" REGN shares.
: According to analysts, Regeneron Pharmaceuticals's stock has a predicted upside of 10.25% based on their 12-month stock forecasts.
: Over the previous 90 days, Regeneron Pharmaceuticals's stock had 1 downgrade by analysts.
: Regeneron Pharmaceuticals has been rated by research analysts at Barclays, BMO Capital Markets, Cantor Fitzgerald, Guggenheim, JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, Morgan Stanley, Piper Sandler, Royal Bank of Canada, TD Cowen, Truist Financial, and Wells Fargo & Company in the past 90 days.
: Analysts like Regeneron Pharmaceuticals less than other "medical" companies. The consensus rating score for Regeneron Pharmaceuticals is 2.77 while the average consensus rating score for "medical" companies is 2.78. Learn more on how REGN compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

AI Expert Reveals New Pick (Ad)

Everyone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released my latest prediction and believe it or not, I’m advising NOT pour all your money into Nvidia right now

Click here to see why

This page (NASDAQ:REGN) was last updated on 10/3/2024 by MarketBeat.com Staff

From Our Partners